Introduction:
The biologic therapies market in the Netherlands is experiencing significant growth in 2026, in line with global trends. With an increasing focus on personalized medicine and advancements in biotechnology, the demand for biologic therapies is on the rise. In 2025, the market size for biologic therapies in the Netherlands was estimated to be €2.5 billion, with a projected annual growth rate of 8%.
Top 10 Biologic Therapies Importers in Netherlands 2026:
1. Johnson & Johnson
Johnson & Johnson is a leading importer of biologic therapies in the Netherlands, with a market share of 15%. The company’s diverse portfolio of biologic products has contributed to its strong performance in the market.
2. Roche
Roche is another key player in the biologic therapies market in the Netherlands, with a market share of 12%. The company’s innovative biologic treatments for cancer and autoimmune diseases have solidified its position in the market.
3. AbbVie
AbbVie is a major importer of biologic therapies in the Netherlands, with a market share of 10%. The company’s biologic products for rheumatoid arthritis and psoriasis have been well-received by healthcare professionals and patients alike.
4. Pfizer
Pfizer is a prominent importer of biologic therapies in the Netherlands, with a market share of 8%. The company’s biologic treatments for rare diseases and oncology have been instrumental in driving its growth in the market.
5. Novartis
Novartis holds a significant market share of 7% in the biologic therapies market in the Netherlands. The company’s biologic products for multiple sclerosis and cancer have been key drivers of its success in the market.
6. Amgen
Amgen is a leading importer of biologic therapies in the Netherlands, with a market share of 6%. The company’s biologic treatments for osteoporosis and cardiovascular diseases have garnered widespread acclaim in the market.
7. Merck
Merck is a key player in the biologic therapies market in the Netherlands, with a market share of 5%. The company’s biologic products for diabetes and infectious diseases have been well-received by healthcare professionals.
8. Bristol-Myers Squibb
Bristol-Myers Squibb is a significant importer of biologic therapies in the Netherlands, with a market share of 4%. The company’s biologic treatments for cancer and cardiovascular diseases have contributed to its strong performance in the market.
9. AstraZeneca
AstraZeneca holds a notable market share of 3% in the biologic therapies market in the Netherlands. The company’s biologic products for respiratory diseases and oncology have been key drivers of its success in the market.
10. Biogen
Biogen is a prominent importer of biologic therapies in the Netherlands, with a market share of 2%. The company’s biologic treatments for multiple sclerosis and Alzheimer’s disease have been instrumental in driving its growth in the market.
Insights:
The biologic therapies market in the Netherlands is expected to continue its growth trajectory in the coming years, driven by advancements in biotechnology and increasing demand for personalized medicine. By 2030, the market size for biologic therapies in the Netherlands is projected to reach €4 billion, with an annual growth rate of 10%. Key trends to watch include the development of biosimilars, expansion into emerging markets, and increased collaboration between pharmaceutical companies and research institutions. As the landscape continues to evolve, companies will need to stay ahead of the curve to remain competitive in the growing biologic therapies market.
Related Analysis: View Previous Industry Report
